Novo Nordisk Raises Outlook Slightly as Q1 Profit Exceeds Forecast
Danish pharmaceutical company Novo Nordisk reported first-quarter revenue and adjusted operating profit above expectations, leading to a slight improvement in its annual outlook. The firm is focusing on demand for its new weight-loss pill Wegovy amid competition with Eli Lilly.
Tickers: $LLY
Topics: Eli Lilly guidance revision obesity drugs pharmaceuticals Wegovy